Nanolipid drug delivery system for neuroimmunomodulation of psoriasis

• Grant number: 17/15807-8
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Duration: July 01, 2018 - March 31, 2019
• Field of knowledge: Biological Sciences - Pharmacology - General Pharmacology
• Principal Investigator: Daniel Roberto Callejon
• Grantee: Daniel Roberto Callejon
• Host Company: Yosen Indústria e Comércio de Produtos para Saúde Ltda
• CNAE: Fabricação de preparações farmacêuticas ; Pesquisa e desenvolvimento experimental em ciências físicas e naturais
• City: Ribeirão Preto
• Associated researchers: Fernando de Queiroz Cunha ; José Carlos Farias Alves Filho ; Thiago Mattar Cunha
• Associated scholarship(s): 18/16880-3 - Nanolipid drug delivery system for neuroimmunomodulation of psoriasis, BP.TT; 18/13945-7 - Nanolipid drug delivery system for neuroimmunomodulation of Psoriasis, BP.PIPE

Abstract

Psoriasis is one of the main skin diseases and provides severe damage to the patient's day life. The incidence of psoriasis can vary between 1 and 11% of the countries population. WHO shows that psoriasis has a significant negative impact on the economy, as an example, psoriasis treatment costs was $ 112 billion in the US in 2013. Patients with psoriasis have sharply demarcated chronic erythematous plaques covered with silvery white scales, which most commonly appear on the elbows, knees, scalp, umbilicus, and lumbar area. The psoriasis treatment is based on the use of corticosteroids, vitamin D analogues, immunomodulators and immunobiologicals (severe cases). Currently, psoriasis' treatment has serious problems, such as: the significant side effects, high cost, uncomfortable administration via, expensive ambulatory monitoring and poor adherence by patients. Topical medicines are the first choice for the treatment of mild to moderate degree and can be used associated with immunobiological treatment. However, topical therapy shows several problems, for example, low efficacy, allergy, inconvenience and cosmetic unacceptability of multiple applications each day. Thus, new topical medicines based on nanocarrier system that provides efficacy, tolerability, compliance, cosmetic acceptability and practicality of application are main demands of the market and patients. Therefore, the aim of this project is the development of topical nanolipid drug delivery systems that provides more penetration, permeation and a sustained release of pharmaceutical active ingredient for neuroimmunomodulation of psoriasis. The project will be divided into the following steps: nanolipid drug delivery systems development, formulations physicochemical characterization, preliminary stability study and evaluation of formulations in psoriasis model in vivo. The lipid ingredients (i.e. phospholipids and oils) and physicochemical properties of nanolipid drug delivery system will provide more penetration and permeation of the actives and additionally lipid ingredients can help in the process of skin repair. Consequently, the development of this project may provide novel and innovative nanolipid drug delivery systems for psoriasis treatment which it is in accordance with patient and market needs (i.e. cosmetic acceptability and tolerability, adherence, convenience). Moreover, in our study, some principles of Good Practices of Manufacturing (GMP) will be performed to ensure safe and traceability of results obtained. This point is important to aid in the technology transfer process and to support pre-requisites of clinical studies. (AU)